Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non–Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked
Year: 2023
Type: article
Source: Clinical Lung Cancer
Authors: J. Nicholas Bodor, Jyoti D. Patel, Heather A. Wakelee, Benjamin P. Levy, Hossein Borghaei, Bruna Pellini, Michael R. Costello, Jonathan E. Dowell, Gene Finley, Chao H. Huang, Joel W. Neal, Jorge J Nieva, Sonam Puri, Mark A. Socinski, Christian Thomas, Eric A. Ross, Samuel Litwin, Margie L. Clapper, Joseph Treat
Institutions: Fox Chase Cancer Center, Northwestern University, Stanford Cancer Institute, Johns Hopkins University, Moffitt Cancer Center, Chester County Hospital, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Allegheny Health Network, University of Kansas Medical Center, University of Southern California, USC Norris Comprehensive Cancer Center, University of Utah, Huntsman Cancer Institute, AdventHealth Orlando, AdventHealth, New England Cancer Specialists
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4376109856